Publications by the Founder

The following is a listing of the extensive publications written by Dr. Wimalawansa on a wide variety of medical topics.

    Calcitonin Gene Peptide Family:

  1. Girgis, S.I., Macdonald, D.W.R., Stevenson, J.C., Bevis, P.J.R., Wimalawansa, S.J., Lynch, C., Self, C.H., Morris, H.R., MacIntyre, I. Calcitonin gene-related peptide: potent vasodilator and major product of the calcitonin gene. Lancet, ii: 14–16, 1985.
  2. Zaidi, M., Bevis, P.J.R., Abeyasekera, G., Girgis, S.I., Wimalawansa, S.J., Morris, H.R., MacIntyre I. The origin of circulating calcitonin gene-related peptide in rat. Journal of Endocrinology, 110: 185–190, 1986.
  3. Wimalawansa S.J., Emson P.C., MacIntyre I. Regional distribution of calcitonin gene-related peptide and its specific binding sites in the rat, with particular reference to the nervous system. Neuroendocrinology, 46: 131–136, 1987.
  4. Wimalawansa S.J., MacIntyre I. The presence of calcitonin gene-related peptide in the human cerebrospinal fluid. Brain, 110: 1647–1655, 1987.
  5. Wimalawansa S.J., Stevenson J.C., Kehely A., Banks L.M., MacIntyre I. Prevention of post-menopausal bone loss with small doses of calcitonin and percutaneous oestrogen. In: Recent Research on Gynecological Endocrinology (Vol. 2) (Eds., Genazzani C.A.R., Petraglia F., Volpe A., Facchinetti F.l.), pp. 239–244, 1988.
  6. Wimalawansa S.J., MacIntyre I. Heterogeneity of plasma calcitonin gene-related peptide: partial characterization of immunoreactive forms. Peptides, 9: 407–410, 1988.
  7. MacIntyre I., Stevenson J.C., Whitehead M.I., Wimalawansa S.J., Banks L.M., Healy M.J.R. Calcitonin for prevention of postmenopausal bone loss. Lancet, i: 900–901, 1988.
  8. Wimalawansa S.J., MacIntyre I. Calcitonin gene-related peptide and its specific binding sites in the cardiovascular system of the rat. International Journal of Cardiology, 20: 29–37, 1988.
  9. Seth R., Motte P., Kehely A., Wimalawansa S.J., Self C., Bellet D., Bohuon C., MacIntyre I. A sensitive and specific enzyme-immunometric assay for human calcitonin using monoclonal antibodies. Journal of Endocrinology, 119: 351–357, 1988.
  10. Wimalawansa S.J., MacIntyre, I. Parathyroid hormone, PTH-related peptide, calcitonin and calcitonin gene-related peptide. In: Macmillan Directory-Genetically Engineered Human Therapeutic Drugs (Eds., Copsey, D.N., Delnatte, S.Y.J.), Pantech Partners, 1988.
  11. Wimalawansa S.J. Sensitive and specific radio-receptor assay for calcitonin gene-related peptide. Journal of Neuroendocrinology, 1:15–19, 1989.
  12. Seth S., Motte P., Kehely A., Wimalawansa S.J., Self C.H., Bohuon C., Bellet D., MacIntyre I. The development of a two-site enzyme immunometric assay (EIA) for calcitonin and its application in the measurement of the hormone in normal subjects, MTC patients and postmenopausal women. Hormone and Metabolic Research, 21: 3–5, 1989.
  13. Wimalawansa S.J., Morris H.R., MacIntyre I. Both α- and ß-calcitonin gene-related peptides are present in plasma, cerebrospinal fluid and spinal cord in man. Journal of Molecular Endocrinology, 3: 247–252, 1989.
  14. McEwan J., Legon S., Wimalawansa S.J., Zaidi M., Dollery C., MacIntyre I. Calcitonin gene-related peptide: a review of its biology and relevance to the cardiovascular system. In: Endocrine Mechanisms in Hypertension (Vol. 2) (Eds., Laragh J. H., Brenner B., Kaplan N.), pp. 287–306, 1989
  15. Datta H.K., Zaidi M., Wimalawansa S.J., Ghatei M.A., Beacham J.L., Bloom S.R., MacIntyre I. In vivo and in vitro effects of amylin-amide on calcium metabolism in the rat and rabbit. Biochemical and Biophysical Research Communications, 162: 876–881, 1989.
  16. Wimalawansa S.J. Calcitonin: Molecular biology, physiology, pathophysiology and its therapeutic uses. In: Advances in Bone Regulatory Factors: Morphology, Biochemistry, Physiology and Pharmacology (Eds., Pecile A., Bernard B.), Plenum Press, pp. 121–160, 1989.
  17. Ghatei M.A., Datta H., Watt D.B., Wimalawansa S.J., Zaidi M., MacIntyre I., Bloom S.R. Amylin and amylin-amide lacks an acute effect on blood glucose and insulin. Journal of Endocrinology, 124: R9–R11, 1990.
  18. Wimalawansa S.J., Morris H.R., Etienne A., Blench I., Panico M., MacIntyre I. Isolation, purification and characterization of beta-hCGRP from human spinal cord. Biochemical and Biophysical Research Communications, 167: 993–1000, 1990.
  19. Zaidi M., Datta H.K., Bevis P.J.R., Wimalawansa S.J., MacIntyre I. Amylin amide: a bone conserving peptide from pancreas. Experimental Physiology, 75: 529–536, 1990.
  20. Brain S.D., Wimalawansa S.J., MacIntyre I., Williams T.J. The demonstration of vasodilatory activity of pancreatic amylin in the rabbit. American Journal of Pathology, 136: 487–490, 1990.
  21. Brain S.D., MacIntyre I., Wimalawansa S.J., Williams T.J. Amylin amide, which is structurally similar to calcitonin gene-related peptide (CGRP), stimulates increased blood flow in vivo. European Journal of Pharmacology, 183: 221, 1990.
  22. Datta H.K., Rafter P.W., Wimalawansa S.J., Chen Z.P., MacIntyre I. CGRP and amylin-amide display a proliferative effect on human umbilical endothelial cells and osteoblast-like osteosarcoma cell-line. Biochemical Society Transactions, 18: 1276, 1990.
  23. Hothersall J.S., Muirhead R.P., Wimalawansa S.J. The effect of amylin and calcitonin gene-related peptide on insulin-stimulated glucose transport in the diaphragm. Biochemical and Biophysical Research Communications, 169: 451–454, 1990.
  24. Wimalawansa S.J. Effects of in vivo stimulation on molecular forms of circulatory calcitonin and calcitonin gene-related peptide in man. Molecular and Cellular Endocrinology, 71:13–19, 1990.
  25. Zaidi M., Moonga B.S., Wimalawansa S.J., Bevis P.J., Legon S., Alam A.S., MacIntyre I., Breimer L.H. Expression and function of calcitonin gene products. In: Vitamins and Hormones: Advances in Research and Applications (Vol.46) (Eds., Aurbach G.D., McCormick D.B.), California, Academic Press, 87–164, 1991.
  26. Wimalawansa S.J. Calcitonin. In: Therapeutic Drugs: A Clinical Pharmacopeia (Eds., Dollery C.T.), C18–C22, Churchill Livingstone, United Kingdom, 1991.
  27. Wimalawansa S.J. Circadian variation of plasma calcitonin gene-related peptide in man. Journal of Neuroendocrinology, 3: 319–322, 1991.
  28. Chance W.T., Balasubramanium A., Zhang F.S., Wimalawansa S.J., Fischer J.E. Anorexia following the intra-hypothalamic administration of amylin. Brain Research, 539: 352–354, 1991.
  29. Wimalawansa SJ. Isolation, purification, characterization, and raising monoclonal antibodies for CGRP receptor. Proceedings of the International Symposium on Calcitonin Gene–Related Peptide, Graz, Austria, 1991. Regulatory Peptides, 34(2): 77, 1991.
  30. Wimalawansa S.J., MacIntyre, I. Calcitonin and calcitonin gene-related peptide receptors. In: Receptor Data for Biological Experiments: A Guide to Drug Selectivity (Eds., Doods H.N., van Meel J.C.A.), Ellis Horwood Ltd., Sussex, England, pp. 138–144, 1991.
  31. Wimalawansa S.J. Age-related increase of calcitonin gene-related peptide in rat thyroid and circulation. Peptides, 12(5): 1143–1147, 1991.
  32. Wimalawansa S.J. Isolation, purification and biochemical characterization of calcitonin gene-related peptide receptors. Proceedings of the First International Symposium on Calcitonin Gene-Related Peptide, Graz, Austria, 1991. Annals of the New York Academy of Sciences, 657: 70–87, 1991.
  33. Zaidi, M., Moonga, B. S., Bevis, P. J., Alam, A. S., Legon, S., Wimalawansa, S., MacIntyre, I., Breimer, L. H. Expression and function of the calcitonin gene products. Vitamins and Hormones, 46: 87-164, 1991.
  34. Wimalawansa S.J., Gunasekera R.D., Datta H.K. Hypocalcaemic actions of amylin-amide in man. Journal of Bone and Mineral Research, 7(9): 1113–1116, 1992.
  35. Krootila K., Oksala O., von Dickhoff K., Wimalawansa S.J., Uusitalo H. Ocular irritative response to YAG laser capsulotomy in rabbits: Release of calcitonin gene-related peptide and effects of methysergide. Current Eye Research, 11: 307–314, 1992.
  36. Wimalawansa, S.J. Isolation, purification, and biochemical characterization of calcitonin gene-related peptide receptors. Annals of New York Academy of Sciences, 657: 70-87, 1992.
  37. Wimalawansa S.J. Age-related changes of tissue content of immunoreactive calcitonin gene-related peptide. Aging–Clinical and Experimental Research, 4(3): 211–217, 1992.
  38. Giuliani S., Wimalawansa S.J., Maggie C.A. Involvement of multiple receptors in the biological effects of calcitonin gene-related peptide and amylin in rat and guinea pig preparations. British Journal of Pharmacology, 107: 510–514, 1992.
  39. Wimalawansa S.J. Long- and short-term side effects and safety of calcitonin in man: A prospective study. Calcified Tissue International, 52(2): 90–93, 1993.
  40. Wimalawansa S.J. CGRP radioreceptor assay: A new diagnostic test for medullary thyroid carcinoma. Journal of Bone and Mineral Research, 8(4): 467–473, 1993.
  41. Wimalawansa S.J., El-Kholy A.A. A comparative study of distribution and biochemical characterization of brain CGRP receptors in five different species. Neuroscience, 54(2): 513–519, 1993.
  42. Wimalawansa S.J. Effects of neonatal capsaicin therapy on plasma contents and tissue levels of immunoreactive-CGRP. Peptides, 14(2): 247–252, 1993.
  43. Wimalawansa S.J., Gunasekera R.D., Zhang F. Isolation, purification and characterization of calcitonin gene-related peptide receptor. Peptides, 14(4): 691–699, 1993.
  44. Wimalawansa S.J. An anti-hypertensive effect of oral calcium supplementation is mediated through the potent vasodilator CGRP. American Journal of Hypertension, 6(11): 996–1002, 1993.
  45. Wimalawansa S.J., Baily F. Validation, role in peri-operative assessment, and clinical applications of an immune-radiometric assay for human calcitonin. Peptides, 16(2): 307–312, 1995.
  46. Bryer-Ash M., Follett L., Hodges N., Wimalawansa S.J. Amylin-mediated reduction in insulin sensitivity corresponds to reduced insulin receptor kinase activity in the rat in vivo. Metabolism, 44(6): 705–711, 1995.
  47. Wimalawansa S.J., Supowit S.C., DiPette D.J. Mechanisms of the antihypertensive effects of dietary calcium and role of calcitonin gene-related peptide in hypertension. Canadian Journal of Physiology and Pharmacology, 73: 981–985, 1995.
  48. Bouali S.M, Wimalawansa S.J., Jolicoeur F.B. In vivo central actions of rat amylin. Regulatory Peptide, 56(2): 167–174, 1995.
  49. Wimalawansa S.J. Purification and biochemical characterization of neuropeptide Y-Y2 receptors. Journal of Biological Chemistry, 270(31): 18523–18530, 1995. B
  50. DiPette D., Wimalawansa S.J. Cardiovascular Actions of Calcitonin Gene-Related Peptide. In: Calcium Regulating Hormones and Cardiovascular Function (Eds., Crass J. III, Avioli L.V.), Chapter 10; 239–252, 1995.
  51. Skofitsch G., Wimalawansa S.J., Jacobowitz D.M., Gubisch W. Comparative immuno-histochemical distribution of amylin-like immunoreactivity in the rat central nervous system. 
Canadian Journal of Physiology and Pharmacology, 73: 945–956, 1995.
  52. D'Este L., Wimalawansa S.J., Renda T.G. Amylin-immunoreactivity is co-stored in a serotonin cell subpopulation of the vertebrate stomach and duodenum. Archives of Histology and Cytology, 58: 537–547, 1995.
  53. Yallampalli C., Dong Y.-L., Wimalawansa S.J. Calcitonin gene-related peptide reverses the hypertension and significantly decreases the fetal mortality in pre-eclampsia rats induced by NG-nitro-L-arginine methyl ester. Human Reproduction, 11(4): 895–899, 1996.
  54. Wimalawansa S.J. Calcitonin gene-related peptide: Molecular genetics, physiology, pathology and therapeutic potentials. Endocrine Reviews, 17(5); 533–585, 1996.
  55. Gangula P.R.R., Supowit S.C., Wimalawansa S.J., Zhao H., Hallman D.M., DiPette D.J., Yallampalli C. Calcitonin gene-related peptide is depressor in NG-nitro-L-arginine methyl ester-induced hypertension during pregnancy. Hypertension, 29(2): 248–253, 1997.
  56. Wimalawansa S.J. Calcitonin gene-related peptide, calcitonin and amylin: A peptide super family. Critical Reviews in Neurobiology, 11(4), 167–239, 1997.
  57. Wimalawansa S.J., Cooper C.W. Calcitonin and osteoporosis. Regulatory Peptide Letters, 7: 39–42, 1997.
  58. Wimalawansa S.J. Combined therapies with calcitonin and corticosteroids, or bisphosphonate for treatment of hypercalcaemia of malignancy. Journal of Bone and Mineral Metabolism, 15: 160–164, 1997.
  59. Yallampalli C., Wimalawansa S.J. Calcitonin gene-related peptide is a mediator of vascular adaptation during hypertension in pregnancy. Trends in Endocrinology and Metabolism, 9(3): 113–117, 1998.
  60. Morara S., Wimalawansa S.J., Rosina A. Monoclonal antibodies reveal expression of the CGRP receptor in Purkinje cells, inter-neurons and astrocytes of rat cerebellar cortex. 
Neuroreport, 9: 3755–3759, 1998.
  61. Wimalawansa S.J., Yallampalli C. Pre-eclamptic toxemia: Potential new therapy based on animal studies. Ceylon Medical Journal, 43: 138–144, 1998.
  62. Dong Y.-L., Gangula P.R., Fang L, Wimalawansa S.J., Yallampalli C. Uterine relaxation responses to calcitonin gene-related peptide and calcitonin gene-related peptide receptor decreased during labor in rats. American Journal of Obstetrics and Gynecology, 179: 497–506, 1998.
  63. Gangula P.R.R., Zhao H., Supowit S., Wimalawansa S.J., DiPette D., Yallampalli C. Pregnancy and steroid hormones enhance the vasodilatory response to calcitonin gene- related peptide (CGRP) in rats. American Journal of Physiology, 176: H284–H288, 1999.
  64. Ye Z., Wimalawansa S.J., Westlund KN. Receptor for calcitonin gene-related peptide: Localization in the dorsal and ventral spinal cord. Neurosciences, 92(4): 1389–1397, 1999.
  65. Yallampalli, C., Gangula, P.R.R., Kondapaka, S., Fang, L., Wimalawansa, S.J. Regulation of calcitonin gene-related peptide receptors in the rat uterus during pregnancy and labor and by progesterone. Biology of Reproduction, 61: 1023–1030, 1999.
  66. Dong Y.-L., Fang L., Kondapaka S., Gangula P.R., Wimalawansa S.J., Yallampalli C. Involvement of calcitonin gene-related peptide in the modulation of human endometrial contractions during pregnancy. Journal of Clinical Investigation, 104: 559–565, 1999.
  67. D’Este L., Vaccaro R., Wimalawansa S.J., Maeda T., Renda T.G. Amylin-immuno-reactivity in monkey hypothalamus. Calcitonin Gene-Related Peptide ’98 (Eds., Poyner D., Marshall I., Brain S.D.), Biology Intelligent unit 10; R.G. Landes Co., Austin, Texas, pp 187–188, 1999.
  68. Gangula P.R.R., Zhao H., Wimalawansa S.J., Supowit S.C., DiPette D.J., Westlund K.N., Gagel R., Yallampalli C. Increased blood pressure in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. Hypertension, 35: 470–475, 2000.
  69. Gangula P.R., Wimalawansa S.J., Yallampalli C. Pregnancy and sex-steroid hormones enhance circulating calcitonin gene-related peptide concentrations in rats. Human Reproduction, 15(4): 949–953, 2000.
  70. Yallampalli C., Wimalawansa S.J. Calcitonin gene-related peptide and pregnancy. The CGRP Family: Calcitonin Gene-Related Peptide, Amylin, and Adrenomedullin (Eds., Poyner D., Marshall I., Brain S.D.), RG Landes Co., Austin, Texas, pp 229–238, 2000.
  71. Gangula P.R.R., Lanlua P., Wimalawansa S.J., Supowit S., DiPette D., Yallampalli C. Regulation of calcitonin gene-related peptide expression in dorsal root ganglia of rats by female sex steroid hormones. Biology of Reproduction, 62: 1033–1039, 2000.
  72. D'Este L., Casini A., Wimalawansa S.J., Renda T.G. Immunohistochemical localization of amylin in rat brainstem. Peptides, 21(11): 1743–1749, 2000.
  73. Morara S., Rosina A., Provini L., Forloni G., Anna Caretti A., Wimalawansa S.J. Calcitonin gene-related peptide receptor expression in the neurons and glia of the developing rat cerebellum: an auto-radiographical and immunohistochemical analysis. Neuroscience, 100(2): 381–391, 2000.
  74. Zhang L., Hoff A.O., Wimalawansa S.J., Cote G., Gagel R., Westlund K.N. Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain, 89: 265–273, 2001.
  75. Halhali A., Wimalawansa S.J., Berentsen V., Avila E., Thota C., Larrea F. Calcitonin gene- and parathyroid hormone-related peptides in preeclampsia: Effects of magnesium sulfate. Obstetrics and Gynecology, 97: 893–897, 2001.
  76. Gangula P.R., Zhao H., Wimalawansa S.J., Supowit S.C., DiPette D.J., Yallampalli C. Pregnancy and steroid hormones enhance the systemic and regional hemodynamic effects of calcitonin gene-related peptide in rats. Biology of Reproduction, 64: 1776–1783, 2001.
  77. D'Este L., Wimalawansa S.J., Renda T.G. Distribution of amylin-immunoreactive neurons in the monkey hypothalamus and their relationships with the histaminergic system. Archives of Histology and Cytology, 64(3): 295–303, 2001.
  78. Classey J.D., Lasalandra M.P., Knight Y.K., Wimalawansa S.J., Goadsby P.J. Immuno-histochemical comparison of CGRP and substance P (peptides and receptors) and NMDAR1 and GLUR1 receptor distribution in the cat trigeminocervical complex. Cephalalgia (Blackwell Science Ltd.), Pharmacology, 21: 351–367, 2001.
  79. Yallampalli C., Chauhan M., Kondapaka S., Wimalawansa S.J. Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. Trends in Endocrinology and Metabolism, 13(6): 263–269, 2002.
  80. Lanlua P., Bukoski R.D., Wimalawansa S.J., Yallampalli C. Effects of pregnancy and female sex-steroid hormones on calcitonin gene-related peptide content of mesenteric artery in rat. Biology of Reproduction, 67: 1430–1434, 2002.
  81. Gangula P.R.R., Wimalawansa S.J., Yallampalli C. Sex hormones enhance hypotensive effects of calcitonin gene-related peptide in aged female rats. Biology of Reproduction, 67: 1881–1887, 2002.
  82. Gangula P.R.R., Dong Y.-L., Wimalawansa S.J., Yallampalli C. Infusion of pregnant rats with calcitonin gene-related peptide (CGRP)8-37, a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth. Biology of Reproduction, 67: 624–629, 2002.
  83. Chauhan M., Thota C.S., Kondapaka S.B., Wimalawansa S.J., Yallampalli C. CGRP receptor heterogeneity: a role for receptor component protein? Trends in Endocrinology, 14(1): 4–6, 2002.
  84. Dong Y.-L., Vegiraju S., Gangula P.R., Kondapaka S.B., Wimalawansa S.J., Yallampalli C. Expression and regulation of calcitonin gene-related peptide receptor in the rat placenta. Biology of Reproduction, 67: 1321–1326, 2002.
  85. Witlin A.G., Li Z.-Y., Wimalawansa S.J., Grady J., Grafe M.R., Yallampalli C. Placental and fetal growth and development in late rat gestation is dependent on adrenomedullin. Biology of Reproduction, 67: 1025–1031, 2002.
  86. Witlin A.G., Gangula P.R.R., Wimalawansa S.J., Grafe M., Grady J.J., Yallampalli C. Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. Hypertension in Pregnancy, 22: 9–24, 2003.
  87. Dong Y.-L., Wimalawansa S.J., Yallampalli C. Effects of steroid hormones on calcitonin gene-related peptide receptors in cultures human myometrium. American Journal of Obstetrics and Gynecology, 188: 466–472, 2003.
  88. Chauhan M., Thota C.S., Kondapaka S., Wimalawansa S.J., Yallampalli C. Evidence for the existence of a new receptor for CGRP, which is not CRLR. Peptides, 24: 65–71, 2003
  89. Witlin A.G., Gangula P.R.R., Wimalawansa S.J., Grafe M., Grady J.J., Yallampalli C. Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. Hypertension in Pregnancy, 22(1): 9–24, 2003.
  90. Fristad I., Vandevska-Radunovic V., Fjeld K., Wimalawansa S.J., Kvinnsland H. NK1-, NK2-, NK3- and CGRP-1-receptors identified in rat oral soft tissues, in bone, and dental hard tissue cells. Cell and Tissue Research, 311(3): 383–391, 2003.
  91. Qing X., Wimalawansa S.J., Keith I.M. Specific N-terminal CGRP fragments mitigate chronic hypoxic pulmonary hypertension in rats. Regulatory Peptides, 110: 93–99, 2003.
  92. Gangula P.R.R., Thota C., Wimalawansa S.J., Bukoski R.D., Yallampalli C. Mechanisms involved in calcitonin gene-related peptide-induced relaxation in pregnant rat uterine artery. Biology of Reproduction, 69(5): 1635–1641, 2003.
  93. Grimes J.P., Wimalawansa S.J. Breast-feeding and postmenopausal osteoporosis. Current Women’s Health Reports, 3(3): 193–198, 2003.
  94. Vandevska-Radunovic V., Fristad I., Wimalawansa S.J., Kvinnsland I.H. CGRP-1 and NK-1 receptors in postnatal, developing rat dental tissues. European Journal of Oral Sciences, 111(6): 497–502, 2003.
  95. Yallampalli C., Kondapaka S.B., Lanlua P., Wimalawansa S.J., Gangula P.R. Female sex steroid hormones and pregnancy regulate receptors for calcitonin gene-related peptide (CGRP) in rat mesenteric arteries, but not in aorta. Biology of Reproduction, 70: 1055–1062, 2004.
  96. Gangula P.R.R., Kondapaka S.B., Lanlua P., Wimalawansa S.J., Yallampalli C. Female sex steroid hormones and pregnancy regulate receptors for calcitonin gene-related peptide in rat mesenteric arteries, but not in aorta. Biology of Reproduction, 70: 1055–1062, 2004.
  97. Chauhan M., Gangula, P.R., Wimalawansa, S.J., Yallampalli C. Studies on the effects of the N-terminal domain antibodies of calcitonin receptor-like receptor and receptor activity-modifying protein 1 on calcitonin gene-related peptide-induced vaso-relaxation in rat uterine artery. Biology of Reproduction, 70: 1658–1663, 2004.
  98. Penchalaneni J., Wimalawansa S.J., Yallampalli C. Adrenomedullin antagonist treatment during early gestation in rats causes feto-placental growth restriction through apoptosis. Biology of Reproduction, 71: 1475–1483, 2004.
  99. Gangula, P.R.R., Lanlua, P., Bukoski, R.D., Wimalawansa, S.J., Yallampalli, C. Mesenteric arterial relaxation to calcitonin gene-related peptide is increased during pregnancy and by sex-steroid hormones. Biology of Reproduction, 71: 1739–1745, 2004.
  100. Wimalawansa S.J. Calcitonin: History, Physiology, Pathophysiology and Therapeutic Applications In: Osteoporosis in Men, Chapter 53; 653-666. 2nd ed. (Eds., Orwoll E., Bilezikian J., Vanderschueren D.), 2010.
  101. Back to top

    Cancer and Hypercalcemia:

  102. Harrison M., James N., Broadley K., Bloom S.R., Armour R., Wimalawansa S.J., Heath D., Waxman J. Somatostatin analogue treatment for malignant hypercalcemia. British Medical Journal, 300: 1312–1313, 1990.
  103. Wimalawansa S.J., MacIntyre, I. Parathyroid hormone, PTH-related peptide, calcitonin and calcitonin gene-related peptide. In: Macmillan Directory-Genetically Engineered Human Therapeutic Drugs (Eds., Copsey, D.N., Delnatte, S.Y.J.), Pantech Partners, 1988.
  104. Davis J.P., Archer D.J., Fisher C., Wimalawansa S.J., Baldwin D. Multiple recurrent giant cell lesions associated with high circulatory parathyroid hormone-related peptide in a young adult. British Journal of Oral and Maxillofacial Surgery, 29: 102–105, 1991.
  105. Wimalawansa S.J. Hypercalcaemia of malignancy: etiology, pathophysiology, and management. Reviews on Endocrine-Related Cancer, 45: 5–24, 1993.
  106. Wimalawansa S.J. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer, 73(8): 2223–2230, 1994.
  107. Wimalawansa S.J. Optimal frequency of administration of pamidronate in patients with hypercalcemia of malignancy. Clinical Endocrinology, 41: 591–595, 1994.
  108. Wimalawansa S.J. Hypercalcaemia of Malignancy: Etiology, Pathogenesis and Clinical Management (Medical Intelligence Unit, Monograph), Springer, NY and R.G. Landes Co., Medical Publishers, Austin, Texas, 1995 [ISBN: 1-57059-286-1].
  109. Cooper C., Li H., Wimalawansa S.J. Cancer-associated hypercalcemia and parathyroid hormone-related peptide: a new peptide with diverse roles. Regulatory Peptide Letters, 7:33–38, 1997.
  110. Wimalawansa S.J. Combined therapies with calcitonin and corticosteroids, or bisphosphonate for treatment of hypercalcaemia of malignancy. Journal of Bone and Mineral Metabolism, 15: 160–164, 1997.
  111. Back to top

    Chronic Kidney Disease (CKD), Water and the Environment:

  112. Wimalawansa, S.A. and Wimalawansa, S.J.  Changing agricultural practices in dry zonal areas and escalating incidences of chronic kidney disease of multi-factorial origin.  Wudpecker Journal of Agriculture and Environment, 3(5), 110-124, 2014 http://www.wudpeckerresearchjournals.org/WJAR/pdf/2014/May/Wimalawansa%20and%20Wimalawansa.pdf https://www.researchgate.net/publication/264978995_Impact_of_changing_agricultural_practices_on_human_health_Chronic_kidney_disease_of_multi-factorial_origin_in_Sri_Lanka?ev=prf_pub
  113. Wimalawansa, SA, Wimalawansa, SJ. Impact of changing agricultural practices on human health: Chronic kidney disease of multi-factorial origin in Sri Lanka. Wudpecker Journal of Agricultural Research, 3(5), 110–124, 2014.
  114. Wimalawansa, S.J. Purification of contaminated water with reverse osmosis: Effective solution of providing clean water for human needs in developing countries. International Journal of Emerging Technology and Advanced Engineering, 3(12), 75-89, 2013.
    http://www.ijetae.com/files/Volume3Issue12/IJETAE_1213_14.pdf
  115. Wimalawansa, Shehani A. and Wimalawansa, Sunil J. Impact of changing agricultural practices on human health: Chronic kidney disease of multi-factorial origin in Sri Lanka. Wudpecker Journal of Agricultural Research, 3(5), 110-124, May 2014.
    http://www.wudpeckerresearchjournals.org/WJAR/pdf/2014/May/Wimalawansa%20and%20Wimalawansa.pdf
  116. Wimalawansa, S.J. Escalating Chronic Kidney Diseases of Multi-factorial Origin in Sri Lanka: Causes, Solutions, and Recommendations. Environmental Health and Preventive Medicine, DOI 10.1007/s12199-014-0395-5. http://link.springer.com/article/10.1007/s12199-014-0395-5. 19(6), 375-394, 2014 https://www.researchgate.net/publication/284733764_Escalating_chronic_kidney_diseases_of_multi-factorial_origin_in_Sri_Lanka_causes_solutions_and_recommendations?ev=prf_pub
  117. Wimalawansa, S.A., Wimalawansa, S.J. Agrochemical-related environmental pollution: Effects on human health. Global Journal of Biology, Agriculture & Health Sciences, 3(3): 72-83, 2014. http://www.gifre.org/admin/papers/gjbahs/72-83-Pollution-vol-3-3-gjbahs.pdf https://www.researchgate.net/publication/284805057_Agrochemical-Related_Environmental_Pollution_Effects_on_Human_Health
  118. Wyne, K.L. and Wimalawansa, S.J. Screening and diagnosis of chronic kidney disease of multi-factorial origin. Proceedings of the 5th International conference of sustainable build environment; “Prevention of CKDmfo from Sri Lanka.” Kandy, Sri Lanka [ICSBE/14/237], 234-243, 2014. https://www.researchgate.net/publication/285582077_SCREENING_AND_DIAGNOSIS_OF_CHRONIC_TUBULAR_KIDNEY_DISEASE_OF_MULTI-FACTORIAL_ORIGIN?ev=prf_pub
  119. Wimalawansa, S.J. Environmental pollution-associated chronic kidney disease of multi-factorial origin in Sri Lanka (CKDmfo). Proceedings of the 5th Int. Conference on Sustainable Built Environment-2014, Kandy, Sri Lanka. Climate Change, Community-Environment and Ecosystem, and Environmental Pollution, and Chronic Kidney Disease [ICSBE/14/244]; 244-520, 2014. https://www.researchgate.net/publication/285582154_ENVIRONMENTAL_POLLUTION-ASSOCIATED_CHRONIC_KIDNEY_DISEASE_OF_MULTI-FACTORIAL_ORIGIN_IN_SRI_LANKA_%28CKDmfo%29
  120. Wimalawansa, S.J. Escalating chronic kidney diseases of multi-factorial origin (CKDmfo) in Sri Lanka: Causes, solutions, and recommendations—update and responses. Environmental Health and Preventive Medicine, http://link.springer.com/article/10.1007/s12199-014-0395-5 DOI 10.1007/s12199-015-0447-5; 20(1): 152–157, 2015.
  121. Wimalawansa, S.A., Wimalawansa, S.J., Clean water, healthy environment, and preservation of watersheds: Correct, enforceable policies are essential. Journal of Hydrology, 1(1): 3-15, 2015. http://www.jacobspublishers.com/index.php/journal-of-hydrology-articles-in-press
  122. Wimalawansa, S.J., The role of ions, heavy metals, and fluoride in chronic kidney disease of multifactorial origin (CKDmfo/CKDuo) in Sri Lanka. Environ Geochem Health, (Epub ahead of print) http://www.ncbi.nlm.nih.gov/pubmed/26462963; DOI 10.1007/s10653-015-9739-3, 
PMID: 26462963, 2015.
  123. Wimalawansa, S.A. and Wimalawansa, S.J. Protection of watersheds and control of fertilisers to prevent phosphate eutrophication of reservoirs in Sri Lanka. International Journal of Research in Environmental Science 1: 2s, 1-19, 2015; https://www.arcjournals.org/pdfs/ijres/v1-i2/1.pdf
  124. Wimalawansa, S.J. The role of ions, heavy metals, fluoride, and agrochemicals: Critical evaluation of potential aetiological factors of chronic kidney disease of multifactorial origin (CKDmfo/CKDu) and Recommendations for Its Eradication. Environ Geochem Health, DOI 10.1007/s10653-015-9768-y; https://www.ncbi.nlm.nih.gov/pubmed/?term=26462963 38 (3): 639-678, 2015. http://link.springer.com/article/10.1007/s10653-015-9768-y https://www.researchgate.net/publication/265860056_Escalating_chronic_kidney_diseases_of_multi-factorial_origin_in_Sri_Lanka_Causes_solutions_and_recommendations
  125. Wimalawansa, S.A. and Wimalawansa, S.J., Clean water, healthy environment, and preservation of watersheds: Correct, enforceable policies are essential. Journal of Hydrology, 1(1): 3-15, 2015. http://www.jacobspublishers.com/index.php/journal-of-hydrology-articles-in-press https://www.researchgate.net/publication/284805124_Jacobs_Journal_of_Hydrology_Clean_Water_
    Healthy_Environment_and_Preservation_of_Watersheds_Correct_Enforceable_Policies_are_Essential?ev=prf_pub
  126. Wimalawansa S.J. Agrochemicals and chronic kidney disease of multifactorial origin: Environmentally-induced occupational exposure Disease. Int. J. Nephrol. & Kidney Failure 1(2): 1-10, 2015, doi http://dx.doi.org/10.16966/2380-5498.111. https://www.sciforschenonline.org/journals/nephrology-kidney/IJNKF-1-111.php
  127. Weeraratne, S. and Wimalawansa, S.J. A Major irrigation project (Accelerated Mahaweli Programme) and the chronic kidney disease of multifactorial origin in Sri Lanka. International Journal of Environmental & Agriculture Research (IJOEAR), 1(6), 16-27, 2015. http://ijoear.com/Paper-October-2015/IJOEAR-OCT-2015-11.pdf https://www.researchgate.net/publication/284805123_A_Major_Irrigation_Project_%28Accelerated_Mahaweli_Programme%29_and_
    the_Chronic_Kidney_Disease_of_Multifactorial_Origin_in_Sri_Lanka?ev=prf_pub
  128. Wimalawansa, S.A. and Wimalawansa, S.J. Chronic kidney disease of multifactorial origin (CKDmfo/CKDu): Escalating incidence and long-term survival estimates. Journal of Urology and Nephrology Research, J.J. Nephro Urol., 2(4): 1-17, 2015.
  129. Wimalawansa S.J. Strategic framework for managing non-communicable diseases: Preventing chronic kidney disease of multi-factorial origin (CKDmfo / CKDu) as an example. Chronic Dis. Int., 2(2): 1-8, 2015.
  130. Wimalawansa, S.J. Effect of water hardness on non-communicable diseases, including chronic kidney disease of multifactorial origin (CKDmfo/CKDuo). J. Environmental Science & Health, 10.15436/2378-6841.16.029, 2 (1), 1-11, 2016.
  131. Wimalawansa, S.A. and Wimalawansa, S.J. Environmentally induced, occupational diseases with emphasis on chronic kidney disease of multifactorial origin affecting tropical countries. 
Annals of Occupational & Environ Med, 28(33), 1-13, 2016. DOI: 10.1186/s40557-016-0119-y; https://aoemj.biomedcentral.com/articles/10.1186/s40557-016-0119-y; http://rdcu.be/npOD https://wimalawansa.org/sites/all/files/Olcott_Oration_2013_b.pdf
  132. Related Newspaper Articles Written by Dr. Wimalawansa

  133. Agro-chemicals and Chronic Kidney Disease: What needs to be donehttp://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=98247
  134. Should Glyphosate be Banned Without Scientific Evidence? Chronic Kidney Disease of Multi-Factorial Origin (CKD-mfo)http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=100405
  135. Water pollution and chronic kidney disease in Sri Lanka http://www.dailymirror.lk/opinion/172-opinion/43526-water-pollution-and-chronic-kidney-disease-in-sri-lanka.html
  136. News 1 http://www.divaina.com/2015/05/07/news07.html
  137. CKDmfo – Urgent Action Needed by the Government http://www.lankaweb.com/news/items/2015/05/07/ckdmfo-urgent-action-needed-by-the-government/M
  138. Myths and Confusions: Chronic Kidney Disease of Multi-Factorial Origin http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=125383
  139. Kidney disease in NCP: Focus on prevention http://www.sundaytimes.lk/150503/sunday-times-2/kidney-disease-in-ncp-focus-on-prevention-147418.html
  140. Series of Weekly Articles in Sinhala http://www.lankadeepa.lk/index.php/articles/326662
  141. Back to top

    Development of New Immunoassays:

  142. Self, C.H., Wimalawansa, S.J., Johannsson, A., Bates, D., Girgis, S.I., MacIntyre, I. A new sensitive and fast peptide immunoassay based on enzyme amplification: used in the determination of CGRP and the demonstration of its presence in the thyroid. Peptides, 6: 627–630, 1985.
  143. Seth R., Motte P., Kehely A., Wimalawansa S.J., Self C., Bellet D., Bohuon C., MacIntyre I. A sensitive and specific enzyme-immunometric assay for human calcitonin using monoclonal antibodies. Journal of Endocrinology, 119: 351–357, 1988.
  144. Wimalawansa S.J. Sensitive and specific radio-receptor assay for calcitonin gene-related peptide. Journal of Neuroendocrinology, 1:15–19, 1989.
  145. Seth S., Motte P., Kehely A., Wimalawansa S.J., Self C.H., Bohuon C., Bellet D., MacIntyre I. The development of a two-site enzyme immunometric assay (EIA) for calcitonin and its application in the measurement of the hormone in normal subjects, MTC patients and postmenopausal women. Hormone and Metabolic Research, 21: 3–5, 1989.
  146. Wimalawansa S.J. CGRP radioreceptor assay: A new diagnostic test for medullary thyroid carcinoma. Journal of Bone and Mineral Research, 8(4): 467–473, 1993.
  147. Wimalawansa S.J., Baily F. Validation, role in peri-operative assessment, and clinical applications of an immune-radiometric assay for human calcitonin. Peptides, 16(2): 307–312, 1995.
  148. Yallampalli, C., Gangula, P.R.R., Kondapaka, S., Fang, L., Wimalawansa, S.J. Regulation of calcitonin gene-related peptide receptors in the rat uterus during pregnancy and labor and by progesterone. Biology of Reproduction, 61: 1023–1030, 1999.
  149. Dong Y.-L., Fang L., Kondapaka S., Gangula P.R., Wimalawansa S.J., Yallampalli C. Involvement of calcitonin gene-related peptide in the modulation of human endometrial contractions during pregnancy. Journal of Clinical Investigation, 104: 559–565, 1999.
  150. Back to top

    General

  151. Wimalawansa, S.J. Use of papaya in the treatment of chronic infected ulcers. Ceylon Medical Journal, 27: 59–61, 1981.
  152. Senanayaka, N., Wimalawansa, S.J. Periodic paralysis complicating malaria. Postgraduate Medical Journal, 57: 273–274, 1981.
  153. Wimalawansa, S.J., Herath, K.B., Wikramanayake, T.W., Piyasena, R.D. Total body water and its relation to body fat. Ceylon Medical Journal, 29: 82–86, 1981.
  154. Herath, K.B., Wimalawansa, S.J., Wikramanayake, T.W., Piyasena, R.D. Estimation of total body water and water turnover rates in Sri Lanka using tritiated water. Journal of National Science Council, 51: 371–378, 1982.
  155. Wimalawansa S.J., Wikramanayake T.W. The ratio: birth weight to maternal weight, as an index of maturity of neonate. Ceylon Journal of Medical Sciences, 30: 39–44, 1987.
  156. Wimalawansa, S.J. Sexually transmitted diseases in the age of AIDS. Ceylon Medical Journal, 38(1):12-14, 1993.
  157. Wimalawansa S.J. Effects of fruits and vegetables on skeletal health. FAV-Health – 2007; [Eds. B Patil, P Murano, M.J. Amiot-Carlin], Acta Horticulturae, 420-431; 2009.
  158. Wimalawansa, S.J. Food fortification programs to alleviate micronutrient deficiencies. 
J. Food Process Technol., 4(8): 257-267, 2013; doi:10.4172/2157- 7110.1000257
  159. Wimalawansa, S.J. Purification of contaminated water with reverse osmosis: Effective solution of providing clean water for human needs in developing countries. [http://www.ijetae.com/files/Volume3Issue12/IJETAE_1213_14.pdf], 
International Journal of Emerging Technology and Advanced Engineering, 3(12), 75-89, 2013.
  160. Back to top

    Nitric Oxide:

  161. Wimalawansa S.J., DeMarco G., Gangula P., Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss [http://www.ncbi.nlm.nih.gov/pubmed/8726385]. 
Bone, 18(4): 301–304, 1996.
  162. Wimalawansa S.J., Chapa M.T., Yallampalli C., Zhang R., Simmons D.J. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats [http://www.ncbi.nlm.nih.gov/pubmed/9276093]. Bone, 21: 275–280, 1997.
  163. Wimalawansa S.J. Restoration of ovariectomy-induced bone loss by nitroglycerin. 
Calcified Tissue International, 66: 56–60, 2000.
  164. Wimalawansa S.J. Restoration of ovariectomy-induced bone loss by nitroglycerin. 
Calcified Tissue International, 66: 56–60, 2000.
  165. Wimalawansa S.M., Chapa T., Fang L., Yallampalli C., Simmons D., Wimalawansa S.J.
Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. Journal of Bone and Mineral Research, 15(6): 1119–1125, 2000.
  166. Wimalawansa S.M., Shankar V.S., Simmons D.J., Wimalawansa S.J. The mechanism of bone resorption by cyclosporine: Involvement of the NO/cGMP pathway. Journal of Musculoskeletal and Neuronal Interactions, 1(2): 141–143, 2000.
  167. Wimalawansa S.J. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans [http://www.ncbi.nlm.nih.gov/pubmed/18056048; 10.1196/annals.1402.066]. Annals of the New York Academy of Sciences, 1117: 283–297, 2007.
  168. Wimalawansa S.J. Nitric oxide: New evidence for novel therapeutic indications [10.1517/14656566.9.11.1935; http://www.ncbi.nlm.nih.gov/pubmed/18627331]. Expert Opinion on Pharmacotherapy, 9(11):1935–1954, 2008.
  169. Wimalawansa, S.J. Nitric oxide: Novel therapy for osteoporosis [10.1517/14656560802197162; http://www.ncbi.nlm.nih.gov/pubmed/19006476]. 
Expert Opinion on Pharmacotherapy, 9(17): 3025–3044, 2008.
  170. Wimalawansa S.J. Skeletal effects of nitric oxide: A novel agent for osteoporosis. In: Principles of Bone Biology, 3rd ed. (Eds., Bilezikian J., Raize L., Martin T.J.), pp. 1275–1311, 2008.
  171. Wimalawansa, S.J., Grimes, J.P., Wilson, A., Hoover, D.R. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone Loss [doi: 10.1210/jc.2008-2225; http://www.ncbi.nlm.nih.gov/pubmed/19549739]. Journal of Clinical Endocrinology & Metabolism, 94(9): 3356–3364, 2009.
  172. Wimalawansa, S.J. Nitric oxide and bone [doi: 1749-6632.2009.05230.x; http://www.ncbi.nlm.nih.gov/pubmed/20392265]. Annals of the New York Academy of Sciences, NY, 1192: 391–403, 2010.
  173. Back to top

    Obesity and Nutrition

  174. Wimalawansa, S.J. Pathophysiology of obesity: Focused, cause-driven approach to control the epidemic. Global Advanced Research Journal of Pharmacy and Pharmacology, 2(1): 2-12, 2013
  175. Wimalawansa S.J.  Controlling obesity and its complications by elimination of causes and adopting healthy habits: “cause-driven” approach.  Advances in Medical Sciences, 3(1): 1-15, 2014.
  176. Wimalawansa, S.J. Stigma of obesity: A major barrier to overcome. Journal of Clinical and Translational Endocrinology [DOI: 10.1016/j.jcte.2014.06.001]. 1(3); 73-76, 2014.
  177. Chance W.T., Balasubramanium A., Zhang F.S., Wimalawansa S.J., Fischer J.E. Anorexia following the intra-hypothalamic administration of amylin. Brain Research, 539: 352–354, 1991.
  178. Wimalawansa, S.J. Visceral adiposity and cardio-metabolic risks: Epidemic of Abdominal Obesity in North America. Research and Reports in Endocrine Disorders, 3: 17-30, 2013.
  179. Wimalawansa, S.J. Food fortification programs to alleviate micronutrient deficiencies. 
J. Food Process Technol., 4(8): 257-267, 2013; doi:10.4172/2157- 7110.1000257
  180. Wimalawansa, S.J. Thermogenesis based interventions for treatment for obesity and type 2 diabetes mellitus. Expert Reviews of Endocrinology & Metabolism, 8(3), 275–288, 2013.
  181. Wimalawansa, S.J. Pathophysiology of obesity: Focused, cause-driven approach to control the epidemic. Global Advanced Research Journal of Pharmacy and Pharmacology, 2(1): 2-12, 2013.
  182. Wimalawansa S.J. Controlling obesity and its complications by elimination of causes and adopting healthy habits: “cause-driven” approach. Advances in Medical Sciences, 3(1): 1-15, 2014.
  183. Smith., G. and Wimalawansa, S.J. Reconciling the Irreconcilable: Micronutrients in Clinical Nutrition and Public Health. Vitamins & Minerals [10.4172/ 2376-1318.1000e136], 4 (1): e136, 2015. http://www.academia.edu/11797603/Reconciling_the_Irreconcilable_Micronutrients_in_Clinical_Nutrition_and_Public_Heal
  184. Wimalawansa, S.J., Obesity and type 2 diabetes: Preventing associated complications. Editorial, Journal of Diabetes, Metabolic Disorders & Control, 2(4): 47-50, 2015. DOI: 10.15406/jdmdc.2015.02.00047 http://medcraveonline.com/JDMDC/JDMDC-02-00047.pdf
  185. Wimalawansa, S.J.  Individualized Approaches to Improve Obesity Management. Sri Lanka Scientist, 2015.
  186. Wimalawansa, S.J.  Losing Weight to Reduce Obesity Associated Complications. Sri Lanka Scientist, 2015.
  187. Wimalawansa, S.J.  Metabolic Syndrome and Associated Complications. Sri Lanka Scientist, 2015.
  188. Wimalawansa, S.J.  Preventing Long Term Complications of Obesity, Type 2 Diabetes, and Metabolic Syndrome. Endocrinol & Metab Syndr., 4(4): 1-6, 2015. doi:10.4172/2161-1017.1000206. http://www.omicsonline.org/open-access/preventing-longterm-complications-of-obesity-type-2-diabetes-andmetabolic-syndrome-2161-1017-1000206.php?aid=65118
  189. Wimalawansa S.J. In the Era of Budgetary Constraints, Cost-Effective Management of Metabolic Syndrome, Type 2 Diabetes, and Obesity is Essential. Current Res Diabetes & Obesity J. 1; 1-5, 2015. http://juniperpublishers.com/crdoj/pdf/CRDOJ.MS.ID.555554.pdf
  190. Wimalawansa S.J. Vitamin D Deficiency is Surrogate Marker for Visceral Fat Content, Metabolic Syndrome, and Future Metabolic Complications. J Diabetes Metab Disord Control, 3(1): 1-10, 2016. DOI: 10.15406/jdmdc.2016.03.00059.
  191. Wimalawansa S.J. Preventing Long-Term Complications of Obesity, Type 2 Diabetes, and Metabolic Syndrome: Common Sense Approach. Endocrinol & Metab Syndr., 4(4): 1-6, 2015. doi:10.4172/2161-1017.1000206. http://www.omicsonline.org/open-access/preventing-longterm-complications-of-obesity-type-2-diabetes-andmetabolic-syndrome-2161-1017-1000206.php?aid=65118
  192. Back to top

    Osteomyelitis of the Jaw:

  193. Wimalawansa S.J. Insight into bisphosphonate-associated osteomyelitis of the jaw: Pathophysiology, mechanisms and clinical management. Expert Opinion on Drug Safety, 7(4): 491–512, 2008.
  194. Wimalawansa S.J. Bisphosphonate-associated osteomyelitis of the jaw: Guidelines for practicing clinicians. Endocrine Practice, 14: 1150–1168, 2008.
  195. Back to top

    Osteoporosis & Paget’s disease:

  196. Wimalawansa S.J.  Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis. [E-Pub, June 2016]. DOI: 10.1080/17446651.2016.1202111; Expert Review of Endocrinology & Metabolism, 11:4, 329-348, 2016; http://www.tandfonline.com/doi/pdf/10.1080/17446651.2016.1202111?needAccess=true
  197. Camacho, PM, Petak, SM, Binkley, NC, Harris, T, Kleerekoper, M, Lewiecki, M, Miller, P, Narula, HS, Pessah-Pollack, R, Tangpricha, V, Wimalawansa, SJ, Watts, N. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016 - executive summary. EDOI: 10.4158/EP161435.ESGL; Endocrine Practice, 22(9):1111-1118, 2016.
  198. Camacho, PM, Petak, SM, Binkley, NC, Harris, T, Kleerekoper, M, Lewiecki, M, Miller, P, Narula, HS, Pessah-Pollack, R, Tangpricha, V, Wimalawansa, SJ, Watts, N. American association of clinical endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis, Endocrine Practice (E-Pub; 19.18.2016).
  199. Wimalawansa S.J., Kehely A., Banks L.M., Stevenson J.C., Endacott J., Whitehead M.I., MacIntyre I. The effect of percutaneous oestradiol and low dose human calcitonin on postmenopausal bone loss. In: Osteoporosis 1987, Proceedings of the International Symposium (Eds., Christiansen C., Johansen J.S., Riis B.J.), Viborg: Norhaven A/S, pp. 528–532, 1987.
  200. Wimalawansa S.J. Osteoporosis: a preventable disease. Bone, 5:4, 1988.
  201. Wimalawansa S.J., Stevenson J.C., Kehely A., Banks L.M., MacIntyre I. Prevention of post-menopausal bone loss with small doses of calcitonin and percutaneous oestrogen. In: Recent Research on Gynecological Endocrinology (Vol. 2) (Eds., Genazzani C.A.R., Petraglia F., Volpe A., Facchinetti F.l.), pp. 239–244, 1988.
  202. Wimalawansa S.J., MacIntyre, I. Can we determine the lowest dose of oestradiol still active on bone? In: Recent Research on Gynecological Endocrinology (Vol. 2) (Eds., Genazzani C.A.R., Petraglia F., Volpe A., Facchinetti F.I.), pp.314–316, 1988.
  203. Wimalawansa S.J. Does the treatment of osteoporosis with estrogens improve skin fragility? Journal of Tissue Viability, 1: 22–25, 1991.
  204. Wimalawansa S.J. Use of plasma 17β-oestradiol as a guideline for parenteral administration of oestrogen for the prevention and treatment of osteoporosis. In: Osteoporosis 1990 (Eds., Christiansen, C., Overgaard, K.), Vol. 3, 1917–1922, 1991.
  205. Wimalawansa, S.J., Banks, L. M. Therapeutic success in severe iatrogenic osteoporosis in a young woman. Journal of Royal Society of Medicine, 86(2): 117-8, 1993.
  206. Wimalawansa S.J., Gunasekera R.D. Pamidronate is effective for Paget’s disease of bone refractory to conventional therapy. Calcified Tissue International, 53(4): 237–241, 1993.
  207. Wimalawansa S.J. Therapeutic options in prevention and treatment of osteoporosis. Experiments in Clin Endocrinology (Life Science Advances), 12:1–27, 1993.
  208. Wimalawansa S.J., Gunasekera, R.D. The effectiveness of pamidronate in patients with Paget's disease of bone refractory to conventional therapy. Seminars in Arthritis and Rheumatism, 23 (1):1–2, 1994.
  209. Wimalawansa, S.J. Dramatic response to plicamycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. Seminars in Arthritis Rheumatism, 23(4):267-8, 1994.
  210. Wimalawansa S.J. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. American Journal of Medicine, 99: 36–42, 1995.
  211. Wimalawansa S.J., DeMarco G., Gangula P., Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss [http://www.ncbi.nlm.nih.gov/pubmed/8726385]. 
Bone, 18(4): 301–304, 1996.
  212. Wimalawansa S.J., Chapa M.T., Yallampalli C., Zhang R., Simmons D.J. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats [http://www.ncbi.nlm.nih.gov/pubmed/9276093]. Bone, 21: 275–280, 1997.
  213. Cooper C., Li H., Wimalawansa S.J. Cancer-associated hypercalcemia and parathyroid hormone-related peptide: a new peptide with diverse roles. Regulatory Peptide Letters, 7:33–38, 1997.
  214. Wimalawansa S.J., Simmons D.J. Prevention of corticosteroid-induced bone loss with alendronate. Proceedings of the Society of Experimental Biology and Medicine, 217: 162–167, 1997.
  215. Wimalawansa S.J. Four-year randomized controlled trial of hormone replacement therapy and bisphosphonate alone or in combination in women with postmenopausal osteoporosis. 
American Journal of Medicine, 104: 219–226, 1998.
  216. Wimalawansa S.M., Chapa M.T., Wei Jingna N., Westlund Karin N., Quast M.J., Wimalawansa S.J. Reversal of weightlessness-induced musculoskeletal losses with androgens: Quantitation by MRI. Journal of Applied Physiology, 86: 1841–1846, 1999.
  217. Wimalawansa S.M., Wimalawansa S.J. Simulated weightlessness-induced attenuation of testosterone production may be responsible for bone loss. Endocrine, 10(3): 253–260, 1999.
  218. Wimalawansa S.J. Restoration of ovariectomy-induced bone loss by nitroglycerin. 
Calcified Tissue International, 66: 56–60, 2000.
  219. Wimalawansa S.J. Restoration of ovariectomy-induced bone loss by nitroglycerin. 
Calcified Tissue International, 66: 56–60, 2000.
  220. Wimalawansa S.M., Chapa T., Fang L., Yallampalli C., Simmons D., Wimalawansa S.J.
Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. Journal of Bone and Mineral Research, 15(6): 1119–1125, 2000.
  221. Wimalawansa S.J. Prevention and treatment of osteoporosis: Efficacy of combined therapies of hormone replacement therapy with anti-resorptive agents. Journal of Clinical Densitometry, 3(2): 1–15, 2000.
  222. Wimalawansa S.M., Wimalawansa S.J. A novel pharmacological approach to prevention of musculoskeletal losses associated with simulated microgravity. Journal of Musculoskeletal and Neuronal Interactions, 1(1): 35–41, 2000.
  223. Wimalawansa S.J. Nitroglycerin therapy is as effective as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: A human pilot clinical study. Journal of Bone and Mineral Research, 15: 2240–2244, 2000.
  224. Wimalawansa S.J. Use of the combination of HRT and a bisphosphonate for prevention and treatment of osteoporosis. Journal of Musculoskeletal and Neuronal Interactions, 1(3): 2000.
  225. Zhang L., Hoff A.O., Wimalawansa S.J., Cote G., Gagel R., Westlund K.N. Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain, 89: 265–273, 2001.
  226. Gunaratne G., Rajapakse C.S., Bassler K., Mohanty K.K., Wimalawansa S.J. Model for bone strength and osteoporotic fractures [http://www.ncbi.nlm.nih.gov/pubmed/11863854]. Physical Review Letters, 88(6): 068101, 2002.
  227. Gunaratne G.H., Mohanty K., Wimalawansa S.J. A model of trabecular bone and an application to osteoporosis. Physica Acta, 315: 98–104, 2002.
  228. Rajapakse C.S., Thomsen J.S., Ortiz J.E., Wimalawansa S.J., Ebbesen E.N., Mosekilde L., Gunaratne G.H. An expression relating breaking stress and density of trabecular bone. Physical Review Letters, 8: 1-21, 2003.
  229. Advani S., Wimalawansa S.J. Bones and nutrition: Common sense supplementation for osteoporosis. Current Women’s Health Reports, 3(3): 187–192, 2003.
  230. Witlin A.G., Gangula P.R.R., Wimalawansa S.J., Grafe M., Grady J.J., Yallampalli C. Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. Hypertension in Pregnancy, 22(1): 9–24, 2003.
  231. Grimes J.P., Wimalawansa S.J. Breast-feeding and postmenopausal osteoporosis. Current Women’s Health Reports, 3(3): 193–198, 2003.
  232. Rajapakse, C.S., Thomsen J.S., Espinoza-Ortiz J.S., Wimalawansa S.J., Ebbesen E.N., Mosekilde L., Gunaratne G.H. An expression relating breaking stress and density of trabecular bone [10.1016/j.jbiomech.2003.12.001; http://www.ncbi.nlm.nih.gov/pubmed/15212930]. 
Journal of Biomechanics, 37(8): 1241–1249, 2004.
  233. Rajapakse C.S., Ortiz J.E., Wimalawansa S.J., Ebbesen E.N., Thomsen J.S., Mosekilde L., Gunaratne G.H. A mathematical model to study properties of trabecular bone. Journal of Biomechanics, 2005.
  234. Klein G.L., Wimalawansa S.J., Kulkarni G., Sherrard D.J., Sanford A.P., Herndon D.N. The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: A double-blind, randomized, controlled study. Osteoporosis International, 16; 631–635, 2005.
  235. Liebschner M.A.K., Mueller R., Wimalawansa S.J., Rajapakse C.S., Gunaratne G.H. Testing two predictions for fracture load using computer models of trabecular bone [10.1529/biophysj.104.057539; http://www.ncbi.nlm.nih.gov/pubmed/15879468]. 
Biophysical Journal, 89(2): 759–767, 2005.
  236. Margolis R.N., Wimalawansa S.J. Novel targets and therapeutics for bone loss. Skeletal development and remodeling in health, disease and aging. Skeletal development and remodeling in health, disease and aging. Annals of the New York Academy of Sciences, 1068; 402–409, 2006.
  237. Wimalawansa S.J. Insight into bisphosphonate-associated osteomyelitis of the jaw: Pathophysiology, mechanisms and clinical management. Expert Opinion on Drug Safety, 7(4): 491–512, 2008.
  238. Wimalawansa S.J. Effects of fruits and vegetables on skeletal health. FAV-Health – 2007; [Eds. B Patil, P Murano, M.J. Amiot-Carlin], Acta Horticulturae, 420-431; 2009.
  239. Wimalawansa, S.J., Grimes, J.P., Wilson, A., Hoover, D.R. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone Loss [doi: 10.1210/jc.2008-2225; http://www.ncbi.nlm.nih.gov/pubmed/19549739]. Journal of Clinical Endocrinology & Metabolism, 94(9): 3356–3364, 2009.
  240. Back to top

    Posttraumatic Stress Disorder (PTSD):

  241. Wimalawansa, S.J. Mechanisms of developing post-traumatic stress disorder: New targets for drug development. CNS & Neurological Disorders & Drug Targets, 13(5): 807-816, 2014.http://www.ncbi.nlm.nih.gov/pubmed/25012621
  242. Wimalawansa, S.J. Endocrinological mechanisms of depressive disorders and ill health, doi.org/10.1586/17446651.2016.1127755, Expert Review of Endocrinology and Metabolism, (1), 9-11, 2016.
  243. Wimalawansa, S.J. Post-traumatic stress disorder: An under-diagnosed and under-treated entity. Comprehensive Research Journal of Medicine and Medical Science, 1(1): 1-12, 2013.
  244. Wimalawansa, S.J. Causes and risk factors for post-traumatic stress disorder: The importance of right diagnosis and treatment. Asian Journal of Medical Sciences, 4(2): 1-13, 2013.
  245. Wimalawansa S.J.  Causes and risk factors for post-traumatic stress disorder:  The importance of right diagnosis and treatment.  Asian Journal of Medical Sciences, 5(2): 1-13, 2014.
  246. Back to top

    Pregnancy and Preeclamptic Toxemia:

  247. Wimalawansa, S.J. Relationship of maternal parity to outcome of pregnancy. Ceylon Medical Journal, 30: 49–53, 1982.
  248. Wimalawansa S.J., Wikramanayake T.W. The ratio: birth weight to maternal weight, as an index of maturity of neonate. Ceylon Journal of Medical Sciences, 30: 39–44, 1987.
  249. Wimalawansa S.J., Wikramanayake T.W. Factors affecting weight gain during pregnancy and the growth of the infant. Ceylon Journal of Medical Sciences, 30: 21–28, 1987.
  250. Yallampalli C., Dong Y.-L., Wimalawansa S.J. Calcitonin gene-related peptide reverses the hypertension and significantly decreases the fetal mortality in pre-eclampsia rats induced by NG-nitro-L-arginine methyl ester. Human Reproduction, 11(4): 895–899, 1996.
  251. Gangula P.R.R., Wimalawansa S.J., Yallampalli C. Progesterone up-regulates vasodilator effects of calcitonin gene-related peptide in NG-nitro-L-arginine methyl ester-induced hypertension. American Journal of Obstetrics and Gynecology, 176(4), 894–900, 1997.
  252. Yallampalli C., Wimalawansa S.J. Calcitonin gene-related peptide is a mediator of vascular adaptation during hypertension in pregnancy. Trends in Endocrinology and Metabolism, 9(3): 113–117, 1998.
  253. Wimalawansa S.J., Yallampalli C. Pre-eclamptic toxemia: Potential new therapy based on animal studies. Ceylon Medical Journal, 43: 138–144, 1998.
  254. Dong Y.-L., Gangula P.R., Fang L, Wimalawansa S.J., Yallampalli C. Uterine relaxation responses to calcitonin gene-related peptide and calcitonin gene-related peptide receptor decreased during labor in rats. American Journal of Obstetrics and Gynecology, 179: 497–506, 1998.
  255. Gangula P.R.R., Zhao H., Supowit S., Wimalawansa S.J., DiPette D., Yallampalli C. Pregnancy and steroid hormones enhance the vasodilatory response to calcitonin gene- related peptide (CGRP) in rats. American Journal of Physiology, 176: H284–H288, 1999.
  256. Dong Y.-L., Fang L., Kondapaka S., Gangula P.R., Wimalawansa S.J., Yallampalli C. Involvement of calcitonin gene-related peptide in the modulation of human endometrial contractions during pregnancy. Journal of Clinical Investigation, 104: 559–565, 1999.
  257. Yallampalli C., Dong Y.-L., Wimalawansa S.J. Calcitonin gene-related peptide reverses the hypertension and significantly decreases the fetal mortality in pre-eclampsia rats induced by NG-nitro-L-arginine methyl ester. Human Reproduction, 11(4): 895–899, 1996.
  258. Gangula P.R.R., Supowit S.C., Wimalawansa S.J., Zhao H., Hallman D.M., DiPette D.J., Yallampalli C. Calcitonin gene-related peptide is depressor in NG-nitro-L-arginine methyl ester-induced hypertension during pregnancy. Hypertension, 29(2): 248–253, 1997.
  259. Yallampalli C., Wimalawansa S.J. Calcitonin gene-related peptide is a mediator of vascular adaptation during hypertension in pregnancy. Trends in Endocrinology and Metabolism, 9(3): 113–117, 1998.
  260. Wimalawansa S.J., Yallampalli C. Pre-eclamptic toxemia: Potential new therapy based on animal studies. Ceylon Medical Journal, 43: 138–144, 1998.
  261. Dong Y.-L., Gangula P.R., Fang L, Wimalawansa S.J., Yallampalli C. Uterine relaxation responses to calcitonin gene-related peptide and calcitonin gene-related peptide receptor decreased during labor in rats. American Journal of Obstetrics and Gynecology, 179: 497–506, 1998.
  262. Gangula P.R.R., Zhao H., Supowit S., Wimalawansa S.J., DiPette D., Yallampalli C. Pregnancy and steroid hormones enhance the vasodilatory response to calcitonin gene- related peptide (CGRP) in rats. American Journal of Physiology, 176: H284–H288, 1999.
  263. Gangula P.R.R., Lanlua P., Wimalawansa S.J., Supowit S., DiPette D., Yallampalli C. Regulation of calcitonin gene-related peptide expression in dorsal root ganglia of rats by female sex steroid hormones. Biology of Reproduction, 62: 1033–1039, 2000.
  264. Gangula P.R., Zhao H., Wimalawansa S.J., Supowit S.C., DiPette D.J., Yallampalli C. Pregnancy and steroid hormones enhance the systemic and regional hemodynamic effects of calcitonin gene-related peptide in rats. Biology of Reproduction, 64: 1776–1783, 2001.
  265. Yallampalli C., Chauhan M., Kondapaka S., Wimalawansa S.J. Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. Trends in Endocrinology and Metabolism, 13(6): 263–269, 2002.
  266. Lanlua P., Bukoski R.D., Wimalawansa S.J., Yallampalli C. Effects of pregnancy and female sex-steroid hormones on calcitonin gene-related peptide content of mesenteric artery in rat. Biology of Reproduction, 67: 1430–1434, 2002.
  267. Gangula P.R.R., Wimalawansa S.J., Yallampalli C. Sex hormones enhance hypotensive effects of calcitonin gene-related peptide in aged female rats. Biology of Reproduction, 67: 1881–1887, 2002.
  268. Gangula P.R.R., Dong Y.-L., Wimalawansa S.J., Yallampalli C. Infusion of pregnant rats with calcitonin gene-related peptide (CGRP)8-37, a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth. Biology of Reproduction, 67: 624–629, 2002.
  269. Chauhan M., Thota C.S., Kondapaka S.B., Wimalawansa S.J., Yallampalli C. CGRP receptor heterogeneity: a role for receptor component protein? Trends in Endocrinology, 14(1): 4–6, 2002.
  270. Dong Y.-L., Vegiraju S., Gangula P.R., Kondapaka S.B., Wimalawansa S.J., Yallampalli C. Expression and regulation of calcitonin gene-related peptide receptor in the rat placenta. Biology of Reproduction, 67: 1321–1326, 2002.
  271. Witlin A.G., Li Z.-Y., Wimalawansa S.J., Grady J., Grafe M.R., Yallampalli C. Placental and fetal growth and development in late rat gestation is dependent on adrenomedullin. Biology of Reproduction, 67: 1025–1031, 2002.
  272. Witlin A.G., Gangula P.R.R., Wimalawansa S.J., Grafe M., Grady J.J., Yallampalli C. Adrenomedullin requires an intact nitric oxide system to function as an endogenous vasodilator in rat gestation. Hypertension in Pregnancy, 22: 9–24, 2003.
  273. Dong Y.-L., Wimalawansa S.J., Yallampalli C. Effects of steroid hormones on calcitonin gene-related peptide receptors in cultures human myometrium. American Journal of Obstetrics and Gynecology, 188: 466–472, 2003.
  274. Chauhan M., Thota C.S., Kondapaka S., Wimalawansa S.J., Yallampalli C. Evidence for the existence of a new receptor for CGRP, which is not CRLR. Peptides, 24: 65–71, 2003
  275. Yallampalli C., Kondapaka S.B., Lanlua P., Wimalawansa S.J., Gangula P.R. Female sex steroid hormones and pregnancy regulate receptors for calcitonin gene-related peptide (CGRP) in rat mesenteric arteries, but not in aorta. Biology of Reproduction, 70: 1055–1062, 2004.
  276. Gangula P.R.R., Kondapaka S.B., Lanlua P., Wimalawansa S.J., Yallampalli C. Female sex steroid hormones and pregnancy regulate receptors for calcitonin gene-related peptide in rat mesenteric arteries, but not in aorta. Biology of Reproduction, 70: 1055–1062, 2004.
  277. Chauhan M., Gangula, P.R., Wimalawansa, S.J., Yallampalli C. Studies on the effects of the N-terminal domain antibodies of calcitonin receptor-like receptor and receptor activity-modifying protein 1 on calcitonin gene-related peptide-induced vaso-relaxation in rat uterine artery. Biology of Reproduction, 70: 1658–1663, 2004.
  278. Penchalaneni J., Wimalawansa S.J., Yallampalli C. Adrenomedullin antagonist treatment during early gestation in rats causes feto-placental growth restriction through apoptosis. Biology of Reproduction, 71: 1475–1483, 2004.
  279. Gangula, P.R.R., Lanlua, P., Bukoski, R.D., Wimalawansa, S.J., Yallampalli, C. Mesenteric arterial relaxation to calcitonin gene-related peptide is increased during pregnancy and by sex-steroid hormones. Biology of Reproduction, 71: 1739–1745, 2004.
  280. Back to top

    Vitamin D:

  281. Smith, G., Wimalawansa S.J., Laillou, A, Sophonneary, P., Un, S., Rathavuth Hong, R., Poirot, E., Kuong, K., Chamnan, C., De los Reyes, F., Wieringa, F.T. High Prevalence of Vitamin D deficiencies in Cambodia: A Common Deficiency in a Sunny Country. Nutrients 2016, 8, 290; doi:10.3390/nu8050290 http://www.mdpi.com/2072-6643/8/5/290/html
  282. Wimalawansa, S.J. Vitamin D adequacy and improvements of comorbidities in persons with intellectual developmental disabilities. J. Childhood & Developmental Disorders, 2(3): 22-33, 2016.
  283. Wimalawansa, S.J. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. DOI: 10.1016/j.jsbmb.2016.09.017; J. Steroid Biochem. Mol. Biol., (in press).
  284. Haq A., Wimalawansa S.J., Pludowski P., Al, F. Clinical practice guidelines for vitamin D in the United Arab Emirates. J. Steroid Biochem. and Mol. Biol., (2016), http://dx.doi.org/10.1016/j.jsbmb.2016.09.021
  285. Wimalawansa, S.J. Non-musculoskeletal Benefits of Vitamin D. J.Steroid Biochem. Mol. Biol., DOI: 10.1016/j.jsbmb.2016.09.016 http://www.sciencedirect.com/science/article/pii/S0960076016302527
  286. Wimalawansa, S.J. Vitamin D: Biology, Physiology, and Pathology, Editorial Garvin J. Diabetes, Metabolic Disorders, (in press).
  287. Wimalawansa S.J. Vitamin D deficiency is surrogate marker for visceral fat content, metabolic syndrome, and future metabolic complications. J Diabetes Metab Disord Control, 3(1): 1-10, 2016. DOI: 10.15406/jdmdc.2016.03.00059.
  288. Wimalawansa, S.J. Extra-Skeletal benefits, Endocrine Functions, and Toxicity of Vitamin D 
(e-Pub; 8.23.2016), J. Endocrinology and Diabetes, 3(1): 1-5, 2016.http://www.symbiosisonlinepublishing.com/endocrinology-diabetes/endocrinology-diabetes52.pdf
  289. Wimalawansa, S.J. Vitamin D Adequacy and Improvements of Comorbidities in Persons with Intellectual and Developmental Disabilities. J. Childhood & Developmental Disorders, 2(3): 22-35, 2016 http://childhood-developmental-disorders.imedpub.com/archive.php
  290. Smith, G., Wimalawansa, S.J.  Reconciling the Irreconcilable: Micronutrients in Clinical Nutrition and Public Health. Vitamins & Minerals [10.4172/ 2376-1318.1000e136], 4 (1): e136, 2015. http://www.academia.edu/11797603/Reconciling_the_Irreconcilable_Micronutrients_in_Clinical_Nutrition_and_Public_Health
  291. Grant W.B., Wimalawansa, S.J., Holick, M.F. Vitamin D supplements and reasonable solar UVB should be recommended to prevent escalating incidence of chronic diseases. doi: http://dx.doi.org/10.1136/bmj.h321, BMJ  2015; 350, h321, 2015.
  292. Wimalawansa S.J. Calciferol. In: Therapeutic Drugs: A Clinical Pharmacopeia (Eds., Dollery C.T.), C13–C17, Churchill Livingstone, United Kingdom, 1991.
  293. Wimalawansa, S.J. Vitamin D in the new millennium [doi 10.1007/s11914-011-0094-8; http://www.ncbi.nlm.nih.gov/pubmed/22249582]. Current Osteoporosis Research 
Current
  294. Osteoporosis Research, 10(1):4-15, 2012.
  295. Wimalawansa, S.J. Vitamin D: What clinicians would like to know. Sri Lanka Journal of Diabetes, Endocrinology and Metabolism; 2: 73-88, 2012
  296. Wimalawansa S.J. Vitamin D: Everything you need to know. Karu Sons, Homagama, Sri Lanka, (Ed. 1.0, 2011/Ed. 1.1, 2012), [ISBN: 978-955-9098-94-2]. https://wimalawansa.org/books_and_publications
  297. Wimalawansa, S.J. Vitamin D: An essential component for skeletal health. In, Skeletal Biology and Medicine II: Bone and cartilage homeostasis and bone disease, Annals of the New York Academy of Sciences, NY, 2012, 1240(1): E1-12, 2012; doi: 10.1111/j.1749-6632.2011.06374.x
  298. Grant W.B., Wimalawansa, S.J., Holick, M.F., Cannell, J.J., Pludowski, P., Lappe, J.M., Pittaway, M., May, P. Emphasizing the Health Benefits of Vitamin D for Those with Neurodevelopmental Disorders and Intellectual Disabilities,http://www.mdpi.com/2072-6643/7/3/1538, doi:10.3390/nu7031538, Nutrients 2015, 7(3), 1538-1564. http://www.bmj.com/content/350/bmj.h321/rr-1
  299. Wimalawansa, S.J. Optimal intakes of vitamin D for persons with intellectual developmental disabilities: Sunlight Isn’t enough, almost everyone needs vitamin D supplements. Exceptional Parenting Magazine (Eparent.com), 38-40, Nov. 2014 https://www.questia.com/magazine/1G1-390188533/optimal-intakes-of-vitamin-d-for-persons-with-intellectual
  300. Back to top

    Engineering and Mathematics

  301. Wimalawansa, S.J. Purification of contaminated water with reverse osmosis: Effective solution of providing clean water for human needs in developing countries. International Journal of Emerging Technology and Advanced Engineering, 3(12), 75-89, 2013.
    http://www.ijetae.com/files/Volume3Issue12/IJETAE_1213_14.pdf
  302. Model for Bone Strength and Osteoporotic Fractures.
    http://www.researchgate.net/publication/11497950_Model_for_bone_strength_and_osteoporotic_fractures
  303. An Expression Relating Breaking Stress and Density of Trabecular Bone.
    http://www.researchgate.net/publication/8495187_An_expression_relating_breaking_stress_and_density_of_trabecular_bone
  304. A Model of Trabecular Bone and an Application to Osteoporosis.
    http://www.researchgate.net/publication/239619164_A_model_of_trabecular_bone_and_an_application_to_osteoporosis
  305. Testing Two Predictions for Fracture Load Using Computer Models of Trabecular Bone.
    http://www.researchgate.net/publication/7862446_Testing_two_predictions_for_fracture_load_using_computer_models_of_trabecular_bone
  306. Use of Magnetic Resonance Imaging to Quantitave Microgravity-Induced Musculo-Skeletal Losses.
    http://www.researchgate.net/publication/227011873_Use_of_magnetic_resonance_imaging_to_quantitave_microgravity-induced_musculo-skeletal_losses
  307. The Use of Reverse Osmosis Methodology for Potable Water.
    http://wimalawansa.org/sites/all/files/ckd_nov_2013/Wimalawansa-Peradeniya-Sym-RO_methodology.pdf
  308. Back to top